tbuckley/cabot-search huggingface dataset:
ECG IMAGING AND SUDDEN CARDIAC DEATH IN BRUGADA SYNDROME
Authors: Luigi Pannone, Cinzia Monaco, Antonio Sorgente, Pasquale Vergara, Paul-Adrian Calburean, Anais Gauthey, Antonio Bisignani, Thiago Osorio, Gaetano Paparella, Robbert Ramak, Ingrid Overeinder, Gezim Bala, Alexandre Almorad, Erwin Stroker, Gudrun Pappaert, Juan Sieira, Pedro Brugada, Mark La Meir, Gian Battista Chierchia, Carlo de Asmundis
Journal: Journal of the American College of Cardiology (2022)
Abstract ES12-1: Monitoring of advanced breast cancer with liquid biopsies
Authors: F Bidard
Journal: Cancer Research (2022)

Abstract This talk will focus on the currently available data supporting the validity and utility of circulating tumor DNA for the monitoring and management of metastatic breast cancers, and provide a perspective on future developments. Citation Format: F Bidard. Monitoring of advanced breast cancer with liquid biopsies [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES12-1.
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Authors: David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski
Journal: Clinical Cancer Research (2021)

Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastatic solid tumors. Patients and Methods: This was a multicenter, dose-finding (phase I), and dose expansion (phase II) study (NCT02705105) in patients with locally advanced or metastatic solid tumors. There were no dose-limiting toxicities in phase I with mogamulizumab 1 mg/kg every week for cycle 1 followed by 1 mg/kg every 2 weeks plus nivolumab 240 mg every 2 weeks intravenously, and cohort expansion occurred at this dose level. Results: All 114 patients treated with mogamulizumab 1 mg/kg plus nivolumab 240 mg in phases I (n = 4) and II (n = 110) were assessed for safety and efficacy. Mogamulizumab plus nivolumab showed acceptable safety and tolerability. Objective response rate was 10.5% [95% confidence interval (CI), 5.6–17.7; 3 complete and 9 partial responses]. Disease control rate was 36.8%. Median duration of response was 14.4 months. Median progression-free survival was 2.6 (95% CI, 2.3–3.1) months, and median overall survival was 9.5 (95% CI, 5.9–13.5) months. Conclusions: Combination of mogamulizumab with nivolumab for treatment of patients with locally advanced or metastatic solid tumors did not result in enhanced efficacy. Tolerability of mogamulizumab 1 mg/kg plus nivolumab 240 mg was acceptable.
COVID-19 and resilience of healthcare systems in ten countries
Authors: Catherine Arsenault, Anna Gage, Min Kyung Kim, Neena R. Kapoor, Patricia Akweongo, Freddie Amponsah, Amit Aryal, Daisuke Asai, John Koku Awoonor-Williams, Wondimu Ayele, Paula Bedregal, Svetlana V. Doubova, Mahesh Dulal, Dominic Dormenyo Gadeka, Georgiana Gordon-Strachan, Damen Haile Mariam, Dilipkumar Hensman, Jean Paul Joseph, Phanuwich Kaewkamjornchai, Munir Kassa Eshetu, Solomon Kassahun Gelaw, Shogo Kubota, Borwornsom Leerapan, Paula Margozzini, Anagaw Derseh Mebratie, Suresh Mehata, Mosa Moshabela, Londiwe Mthethwa, Adiam Nega, Juhwan Oh, Sookyung Park, Álvaro Passi-Solar, Ricardo Pérez-Cuevas, Alongkhone Phengsavanh, Tarylee Reddy, Thanitsara Rittiphairoj, Jaime C. Sapag, Roody Thermidor, Boikhutso Tlou, Francisco Valenzuela Guiñez, Sebastian Bauhoff, Margaret E. Kruk
Journal: Nature Medicine (2022)

Abstract Declines in health service use during the Coronavirus Disease 2019 (COVID-19) pandemic could have important effects on population health. In this study, we used an interrupted time series design to assess the immediate effect of the pandemic on 31 health services in two low-income (Ethiopia and Haiti), six middle-income﻿ (Ghana, Lao People’s Democratic Republic, Mexico, Nepal, South Africa and Thailand) and high-income (Chile and South Korea) countries. Despite efforts to maintain health services, disruptions of varying magnitude and duration were found in every country, with no clear patterns by country income group or pandemic intensity. Disruptions in health services often preceded COVID-19 waves. Cancer screenings, TB screening and detection and HIV testing were most affected (26–96% declines). Total outpatient visits declined by 9–40% at national levels and remained lower than predicted by the end of 2020. Maternal health services were disrupted in approximately half of the countries, with declines ranging from 5% to 33%. Child vaccinations were disrupted for shorter periods, but we estimate that catch-up campaigns might not have reached all children missed. By contrast, provision of antiretrovirals for HIV was not affected. By the end of 2020, substantial disruptions remained in half of the countries. Preliminary data for 2021 indicate that disruptions likely persisted. Although a portion of the declines observed might result from decreased needs during lockdowns (from fewer infectious illnesses or injuries), a larger share likely reflects a shortfall of health system resilience. Countries must plan to compensate for missed healthcare during the current pandemic and invest in strategies for better health system resilience for future emergencies.
PEDIATRIC CONTINUOUS-FLOW TOTAL ARTIFICIAL HEART PERFORMANCE: EARLY IN VIVO ASSESSMENT REPORT
Authors: Chihiro Miyagi, Taiyo Kuroda, Barry Dean Kuban, Christine R. Flick, Anthony R. Polakowski, Kiyotaka Fukamachi, Jamshid Karimov
Journal: Journal of the American College of Cardiology (2022)
MEDICAL THERAPY VS. REVASCULARIZATION IN LEFT MAIN CORONARY ARTERY DISEASE WITH PROVEN ISCHEMIA: INSIGHTS FROM THE DEFINE-LM REGISTRY
Authors: Takayuki Warisawa, Christopher Cook, Yoshiaki Kawase, James Howard, Masafumi Nakayama, Yousif Ahmad, Henry Seligman, Christopher Rajkumar, Shunichi Doi, Akihiro Nakajima, Sonoka Goto, Rafael Vera-Urquiza, Yuetsu Kikuta, Amir Lerman, Yoshihiro John Akashi, Javier Escaned, Hitoshi Matsuo, Justin E. Davies
Journal: Journal of the American College of Cardiology (2022)
Effect of desert dust storms and meteorological factors on respiratory diseases
Authors: Mustafa Boğan, Seval Kul, Behçet Al, Mehmet Murat Oktay, Müge Akpinar Elçi, Kent E. Pinkerton, Hasan Bayram
Journal: Allergy (2022)

The authors declare that they have no competing interests. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies
Authors: Filippo Dragoni, Elisabetta Schiaroli, Valeria Micheli, Lia Fiaschi, Alessia Lai, Gianguglielmo Zehender, Barbara Rossetti, Maria Rita Gismondo, Daniela Francisci, Maurizio Zazzi, Ilaria Vicenti
Journal: Clinical Microbiology and Infection (2022)
Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD
Authors: Mathias Hohl, Simina-Ramona Selejan, Jan Wintrich, Ulrike Lehnert, Thimoteus Speer, Clara Schneider, Muriel Mauz, Philipp Markwirth, Dickson W.L. Wong, Peter Boor, Andrey Kazakov, Martin Mollenhauer, Benedikt Linz, Barbara Mara Klinkhammer, Ulrich Hübner, Christian Ukena, Julia Moellmann, Michael Lehrke, Stefan Wagenpfeil, Christian Werner, Dominik Linz, Felix Mahfoud, Michael Böhm
Journal: Circulation Research (2022)

In patients with chronic kidney disease (CKD), atrial fibrillation (AF) is highly prevalent and represents a major risk factor for stroke and death. CKD is associated with atrial proarrhythmic remodeling and activation of the sympathetic nervous system. Whether reduction of the sympathetic nerve activity by renal denervation (RDN) inhibits AF vulnerability in CKD is unknown.Left atrial (LA) fibrosis was analyzed in samples from patients with AF and concomitant CKD (estimated glomerular filtration rate [eGFR], <60 mL/min per 1.73 m2) using picrosirius red and compared with AF patients without CKD and patients with sinus rhythm with and without CKD. In a translational approach, male Sprague Dawley rats were fed with 0.25% adenine (AD)-containing chow for 16 weeks to induce CKD. At week 5, AD-fed rats underwent RDN or sham operation (AD). Rats on normal chow served as control. After 16 weeks, cardiac function and AF susceptibility were assessed by echocardiography, radiotelemetry, electrophysiological mapping, and burst stimulation, respectively. LA tissue was histologically analyzed for sympathetic innervation using tyrosine hydroxylase staining, and LA fibrosis was determined using picrosirius red.Sirius red staining demonstrated significantly increased LA fibrosis in patients with AF+CKD compared with AF without CKD or sinus rhythm. In rats, AD demonstrated LA structural changes with enhanced sympathetic innervation compared with control. In AD, LA enlargement was associated with prolonged duration of induced AF episodes, impaired LA conduction latency, and increased absolute conduction inhomogeneity. RDN treatment improved LA remodeling and reduced LA diameter compared with sham-operated AD. Furthermore, RDN decreased AF susceptibility and ameliorated LA conduction latency and absolute conduction inhomogeneity, independent of blood pressure reduction and renal function.In an experimental rat model of CKD, RDN inhibited progression of atrial structural and electrophysiological remodeling. Therefore, RDN represents a potential therapeutic tool to reduce the risk of AF in CKD, independent of changes in renal function and blood pressure.
TRIPLE ACUTE AORTIC SYNDROME: CONCOMITANT PRESENTATION OF DISSECTION, PENETRATING ATHEROSCLEROTIC ULCER AND HEMATOMA WITH ADEQUATE RESOLUTION THROUGH INTERVENTIONAL THERAPY
Authors: Juan Alan Fuentes Mendoza, Jorge Antonio Cervantes Nieto, Jardiel Arguello, Mario Ramón García Arias, Jose Ramon Benitez, Dulce Aguilera, Juan Fuentes Jaime
Journal: Journal of the American College of Cardiology (2022)
Matrikines as mediators of tissue remodelling
Authors: Nathan Jariwala, Matiss Ozols, Mike Bell, Eleanor Bradley, Andrew Gilmore, Laurent Debelle, Michael J. Sherratt
Journal: Advanced Drug Delivery Reviews (2022)

Extracellular matrix (ECM) proteins confer biomechanical properties, maintain cell phenotype and mediate tissue repair (via release of sequestered cytokines and proteases). In contrast to intracellular proteomes, where proteins are monitored and replaced over short time periods, many ECM proteins function for years (decades in humans) without replacement. The longevity of abundant ECM proteins, such as collagen I and elastin, leaves them vulnerable to damage accumulation and their host organs prone to chronic, age-related diseases. However, ECM protein fragmentation can potentially produce peptide cytokines (matrikines) which may exacerbate and/or ameliorate age- and disease-related ECM remodelling. In this review, we discuss ECM composition, function and degradation and highlight examples of endogenous matrikines. We then critically and comprehensively analyse published studies of matrix-derived peptides used as topical skin treatments, before considering the potential for improvements in the discovery and delivery of novel matrix-derived peptides to skin and internal organs. From this, we conclude that while the translational impact of matrix-derived peptide therapeutics is evident, the mechanisms of action of these peptides are poorly defined. Further, well-designed, multimodal studies are required.
KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub
Authors: Stefano Scalera, Marco Mazzotta, Clelia Cortile, Eriseld Krasniqi, Ruggero De Maria, Federico Cappuzzo, Gennaro Ciliberto, Marcello Maugeri-Saccà
Journal: Journal of Thoracic Oncology (2022)
15P STELLAR-001: A phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors
Authors: J. Bennouna, Y. Touchefeu, F. Ghiringhelli, N. Isambert, F. Barlesi, P. Tomasini, P. Cassier, J. Edeline, S.M. Le Sourd, D. Tosi, A.W. Tolcher, T. Marron, D.B. Marie, J. Viotti, A. Boyer Chammard, P. Martin Romano, C. Massard
Journal: Annals of Oncology (2022)
DIAGNOSTIC PERFORMANCE OF 18F-FDG-PET FOR THE EVALUATION OF CARDIAC SARCOIDOSIS USING STANDARDIZED KETOGENIC DIET
Authors: Ghazaleh Goldar, Erika Hutt, Wael A. Jaber, Ziad Taimeh, Manuel Ribeiro Neto, Christine Louise Jellis, Paul Cremer
Journal: Journal of the American College of Cardiology (2022)
Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects
Authors: Ying Shang, Hannes Hagström
Journal: Clinical Gastroenterology and Hepatology (2022)

Patients with nonalcoholic fatty liver disease (NAFLD) often have hyperlipidemia and are at a higher risk of cardiovascular disease (CVD).1 As first-line lipid-lowering drugs, statins are widely used for primary and secondary CVD prevention.2 However, there have been concerns about statins underprescription for patients with NAFLD because of fear of hepatoxicity.3 We aimed to describe and compare the pattern of statins use before and after CVD events in patients with NAFLD with the general population.
Novel Use of Patient-Specific Covariates From Oncology Studies in the Era of Biomedical Data Science: A Review of Latest Methodologies
Authors: Ronghui Xu, Guanhua Chen, Michael Connor, James Murphy
Journal: Journal of Clinical Oncology (2022)

In this article, we review different applications of how to incorporate individual patient variables into clinical research within oncology. These methodologies range from the more traditional use of baseline covariates from randomized clinical trials, as well as observational studies, to using covariates to generalize the results of randomized clinical trials to other populations. Individual patient variables also allow for the consideration of heterogeneity in treatment effects and individualized treatment rules. We primarily consider two treatment groups and mostly focus on time-to-event outcomes where such methodologies have been well established and widely applied. We also discuss more conceptually newer statistical research that has not been widely applied in clinical oncology, but is likely to make an impact in future oncology research. With the increasing amount of biomedical data available for analysis, it is inevitable that more methods are developed to make best use of information, to advance oncology research.
SPONTANEOUS CORONARY ARTERY DISSECTION. DEMOGRAPHIC AND ANGIOGRAPHIC CHARACTERISTICS FINDINGS IN THE SCALIBUR BRAZILIAN REGISTRY
Authors: Paula Santiago Teixeira, Carlos Campos, Jose de Ribamar Costa, Henrique B. Ribeiro, José Armando Mangione, Marcos Oliveira, Bárbara Freitas, Jamil Ribeiro Cade, Walter B. Fiorotto, Augusto Da Silva, Diego Silveira Da Costa, Cleverson Zuwoski, Marcelo Jose de Carvalho Cantarelli, Gustavo Rocha, Pedro Lemos, Marcelo Franken, Breno Almeida
Journal: Journal of the American College of Cardiology (2022)
Promise of Early Intervention for Children Exposed to Lead
Authors: Mona Hanna-Attisha, Nicole Hamp, Lauren O’Connell
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Publisher Correction: Neural fragility as an EEG marker of the seizure onset zone
Authors: Adam Li, Chester Huynh, Zachary Fitzgerald, Iahn Cajigas, Damian Brusko, Jonathan Jagid, Angel O. Claudio, Andres M. Kanner, Jennifer Hopp, Stephanie Chen, Jennifer Haagensen, Emily Johnson, William Anderson, Nathan Crone, Sara Inati, Kareem A. Zaghloul, Juan Bulacio, Jorge Gonzalez-Martinez, Sridevi V. Sarma
Journal: Nature Neuroscience (2022)
QIM22-189: Harnessing Pathway Power: Development of a Clinical Pathway Program in a Comprehensive Cancer Center for Improved EOL Care and Beyond
Authors: Jonathan Burlison, Rebecca Quillivan, Arshia Madni, Deena Levine
Journal: Journal of the National Comprehensive Cancer Network (2022)

"QIM22-189: Harnessing Pathway Power: Development of a Clinical Pathway Program in a Comprehensive Cancer Center for Improved EOL Care and Beyond" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Multi-omics analysis dissects the genetic architecture of seed coat content in Brassica napus
Authors: Yuting Zhang, Hui Zhang, Hu Zhao, Yefan Xia, Xiangbo Zheng, Ruyi Fan, Zengdong Tan, Chenhua Duan, Yansong Fu, Long Li, Jiang Ye, Shan Tang, Honghong Hu, Weibo Xie, Xuan Yao, Liang Guo
Journal: Genome biology (2022)

Abstract Background Brassica napus is an important vegetable oil source worldwide. Seed coat content is a complex quantitative trait that negatively correlates with the seed oil content in B. napus . Results Here we provide insights into the genetic basis of natural variation of seed coat content by transcriptome-wide association studies (TWAS) and genome-wide association studies (GWAS) using 382 B. napus accessions. By population transcriptomic analysis, we identify more than 700 genes and four gene modules that are significantly associated with seed coat content. We also characterize three reliable quantitative trait loci (QTLs) controlling seed coat content by GWAS. Combining TWAS and correlation networks of seed coat content-related gene modules, we find that BnaC07.CCR-LIKE ( CCRL ) and BnaTT8s play key roles in the determination of the trait by modulating lignin biosynthesis. By expression GWAS analysis, we identify a regulatory hotspot on chromosome A09, which is involved in controlling seed coat content through BnaC07.CCRL and BnaTT8s . We then predict the downstream genes regulated by BnaTT8s using multi-omics datasets. We further experimentally validate that BnaCCRL and BnaTT8 positively regulate seed coat content and lignin content. BnaCCRL represents a novel identified gene involved in seed coat development. Furthermore, we also predict the key genes regulating carbon allocation between phenylpropane compounds and oil during seed development in B. napus . Conclusions This study helps us to better understand the complex machinery of seed coat development and provides a genetic resource for genetic improvement of seed coat content in B. napus breeding.
Diagnostic Strategy Using an Elevated Age-Adjusted D-Dimer Threshold and Thromboembolic Events in the Emergency Department—Reply
Authors: Yonathan Freund, Anthony Chauvin, Ben Bloom
Journal: JAMA (2022)

In Reply We agree that the definition of the failure rate is controversial and that the denominator should be the number of patients in whom the strategy was effectively applied.1 In our study,2 this represented 80% of the population (patients with a YEARS score of 0).
CARDIOLOGISTS IN THE MAKING - INVESTMENTS IN INCLUSION AND INTERPROFESSIONAL DEVELOPMENT AMONG ACC MEDICAL STUDENT MEMBERS
Authors: Adriana Camila Mares, Anusha Gandhi, Christian Faaborg-Andersen, Dan B. Tran, Kevin A. Paternostro, Mariana L. Henry, Lena E. Trager, Emily Gates, Sagarika Arogyaswamy, Samip Sheth
Journal: Journal of the American College of Cardiology (2022)
A LEFT ATRIAL THROMBUS COMPLICATED BY SYSTEMIC EMBOLISM IN A PATIENT WITH CARDIAC AMYLOIDOSIS IN SINUS RHYTHM
Authors: Hiroyoshi Yamaguchi, Yuki Nishimura, Yoko Nakaoka, Junya Komatsu, Hiroki Sugane, Hayato Hosoda, Ryu-ichiro Imai, Koji Nishida, Shu-ichi Seki, Shoichi Kubokawa, Kazuya Kawai, Naohisa Hamashige, Yoshinori L. Doi
Journal: Journal of the American College of Cardiology (2022)
Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
Authors: Zhen-Hua Wu, Na Li, Xiao-Feng Mei, Juan Chen, Xiao-Ze Wang, Ting-Ting Guo, Gang Chen, Lei Nie, Yao Chen, Mei-Zhu Jiang, Ji-Teng Wang, Hai-Bin Wang
Journal: Journal for ImmunoTherapy of Cancer (2022)

The CD47-SIRPα pathway acts as an important myeloid cell immune checkpoint and targeting the CD47/SIRPα axis represents a promising strategy to promote antitumor immunity. Several CD47-targeting agents show encouraging early activity in clinical trials. However, due to ubiquitous expression of CD47, the antigen sink and hematologic toxicity, such as anemia and thrombocytopenia, are main problems for developing CD47-targeting therapies. Considering the limited expression of SIRPα, targeting SIRPα is an alternative approach to block the CD47-SIRPα pathway, which may result in differential efficacy and safety profiles.SIRPα-targeting antibody BR105 was generated by hybridoma fusion and following humanization. BR105 was characterized for binding to human SIRPα alleles and blockade of the interaction with CD47. The functional activity was determined in in vitro phagocytosis assays by using human macrophages. The effect of BR105 on human T cell activation was studied using an OKT3-induced T-cell proliferation assay and an allogeneic mixed lymphocyte reaction. Human SIRPα-humanized immunodeficient mice were used in cancer models for evaluating the in vivo antitumor efficacy of BR105. Safety was addressed in a repeat-dose toxicity study in cynomolgus monkeys, and toxicokinetic analysis was further evaluated.BR105 shows broad binding activity across various SIRPα variants, and potently blocks the interaction of SIRPα and CD47. In vitro functional assays demonstrated that BR105 synergizes with therapeutic antibodies to promote phagocytosis of tumor cells. Moreover, the combination of BR105 and therapeutic antibody significantly inhibits tumor growth in a xenograft tumor model. Although BR105 may slightly bind to SIRPγ, it does not inhibit T cell activation, unlike other non-selective SIRPα-targeting antibody and CD47-targeting agents. Toxicity studies in non-human primates show that BR105 is well tolerated with no treatment-related adverse effects noted.The novel and differentiated SIRPα-targeting antibody, BR105, was discovered and displays promising antitumor efficacy in vitro and in vivo. BR105 has a favorable safety profile and shows no adverse effects on T cell functionality. These data support further clinical development of BR105, especially as a therapeutic agent to enhance efficacy when used in combination with tumor-targeting antibodies or antibodies that target other immune checkpoints.
34P Efficacy and toxicity analysis of imatinib in newly diagnosed patients of chronic myeloid leukaemia: 18-years’ experience at a single large-volume centre
Authors: R. Yadav, S. Parikh, H. Panchal, A. Patel, A. Garg, K. Shah, P. Basu, V.C. Patel, S.R. Ganta, S. Ravichandran, D. Banerjee
Journal: Annals of Oncology (2022)